# Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

> **NCT05696626** · PHASE3 · RECRUITING · sponsor: **LeonaBio** · enrollment: 500 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Lasofoxifene in combination with abemaciclib
- **DRUG:** Fulvestrant in combination with abemaciclib

## Key facts

- **NCT ID:** NCT05696626
- **Lead sponsor:** LeonaBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05696626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05696626, "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05696626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*